In the recent past, pharmaceutical expenditure has been steadily increasing, but the productivity of the sector—measured as the number of New Molecular Entities (NMEs)—has been decreasing. In this chapter we review and analyse the price regulation policies that are currently used by regulators worldwide and we will describe the salient features of these policies from a public health point of view. We will also discuss this in terms of their impact on innovation.
Drug Prices and Incentives to Innovation by the Pharmaceutical Industry
PERTILE, Paolo
2015-01-01
Abstract
In the recent past, pharmaceutical expenditure has been steadily increasing, but the productivity of the sector—measured as the number of New Molecular Entities (NMEs)—has been decreasing. In this chapter we review and analyse the price regulation policies that are currently used by regulators worldwide and we will describe the salient features of these policies from a public health point of view. We will also discuss this in terms of their impact on innovation.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
